The predictive variables assessed were age at EGPA diagnosis, baseline eosinophil count, history of chronic sinusitis prior to diagnosis, and glucocorticoid-treated asthma at diagnosis.
The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.
Doctors in Central Texas share the latest on flu strains, RSV, stomach viruses and cedar pollen as cold and allergy season ...
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...
The FDA granted approval to dupilumab for treating patients aged 6 years and up with allergic fungal rhinosinusitis and a history of sino-nasal surgery, marking the first treatment approved for this ...
Facial swelling can stem from allergies, infections, sinus issues or underlying disease.
Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.
Anyone having difficulty getting a GP appointment could jump the line if they have one of seven conditions, according to TV ...
Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...
Anyone having difficulty getting a GP appointment could jump the line if they have one of seven conditions, according to TV ...
Asthma biologics were not found to correlate with any increased risk to respiratory infections, however, some biologics were linked to a decreased risk of pneumonia, according to new research being ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results